With over 20 years in the pharmaceutical industry, Erhardt brings extensive experience in clinical drug development.
Erhardt is a seasoned pharmaceutical executive with broad global experience in medical, clinical operations and development.
He is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development as well as all aspects of medical product support.
His background is complimented by significant organizational design and leadership experience.
Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse.
He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children's National Medical Center.
In addition, Dr. Erhardt has served as a Staff Fellow at the US Food and Drug Administration. Dr. Erhardt is a Fellow of the American Academy of Pediatrics.
Most recently, Dr. Erhardt was senior vice president, Head of Clinical Development and Operations at Pfizer, Inc. responsible for design, conduct and reporting of Pfizer's global Clinical Development portfolio.
He oversaw Pfizer's Clinical, Clinical Sciences, Clinical Project Management and Study Management functions as well as Pfizer's Internal Phase I Clinical Research units in New Haven and Brussels, Belgium.
In this role, Dr. Erhardt was responsible for all Clinical Development functions for a portfolio of 350 clinical studies across the Cardiovascular, Metabolic Neuroscience, Vaccines, Immunology and Inflammation and Rare Disease therapeutic areas.
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer's disease and related dementias by targeting tau self-association.
The company's drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program.
Oligomerix's small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream.
The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programmes.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial